Literature DB >> 7032803

Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

N H Holford, L B Sheiner.   

Abstract

Mesh：

Substances：

Year:  1981        PMID： 7032803     DOI： 10.2165/00003088-198106060-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  58 in total

1.  Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study.

Authors:  G G Hunder; S G Sheps; G L Allen; J W Joyce
Journal:  Ann Intern Med       Date:  1975-05       Impact factor: 25.391

2.  Response optimization of drug dosage: antiarrhythmic studies with tocainide.

Authors:  P J Meffin; R A Winkle; T F Blaschke; J Fitzgerald; D C Harrison; S R Harapat; P A Bell
Journal:  Clin Pharmacol Ther       Date:  1977-07       Impact factor: 6.875

3.  Pharmacokinetics of digoxin: relationship between response intensity and predicted compartmental drug levels in man.

Authors:  W G Kramer; A J Kolibash; R P Lewis; M S Bathala; J A Visconti; R H Reuning
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

4.  Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

Authors:  M M Reidenberg; I Odar-Cederlöf; C von Bahr; O Borgå; F Sjöqvist
Journal:  N Engl J Med       Date:  1971-07-29       Impact factor: 91.245

5.  Rational intravenous doses of theophylline.

Authors:  P A Mitenko; R I Ogilvie
Journal:  N Engl J Med       Date:  1973-09-20       Impact factor: 91.245

6.  Plasma levels and effects of metoprolol after single and multiple oral doses.

Authors:  P Collste; K Haglund; C von Bahr
Journal:  Clin Pharmacol Ther       Date:  1980-04       Impact factor: 6.875

Review 7.  Pharmacokinetic and pharmacodynamic modeling in vivo.

Authors:  N H Holford; L B Sheiner
Journal:  Crit Rev Bioeng       Date:  1981

8.  Modeling of drug response in individual subjects.

Authors:  A W Kelman; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1980-04

9.  Systems and microcomputer approach to anticoagulant therapy.

Authors:  W F Powers; P H Abbrecht; D G Covell
Journal:  IEEE Trans Biomed Eng       Date:  1980-09       Impact factor: 4.538

10.  Relationship between concentration and anticoagulant effect of heparin in plasma of normal subjects: magnitude and predictability of interindividual differences.

Authors:  L R Whitfield; G Levy
Journal:  Clin Pharmacol Ther       Date:  1980-10       Impact factor: 6.875
View more
  295 in total

1.  Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy.

Authors:  B Vadher; D L Patterson; M Leaning
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

2.  Peripheral link model as an alternative for pharmacokinetic-pharmacodynamic modeling of drugs having a very short elimination half-life.

Authors:  J Laurin; F Donati; F Nekka; F Varin
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-02       Impact factor: 2.745

3.  Implications for clinical pharmacodynamic studies of the statistical characterization of an in vitro antiproliferation assay.

Authors:  L M Levasseur; H Faessel; H K Slocum; W R Greco
Journal:  J Pharmacokinet Biopharm       Date:  1998-12

4.  Postantibiotic suppression of growth of erythromycin A-susceptible and -resistant gram-positive bacteria by the ketolides telithromycin (HMR 3647) and HMR 3004.

Authors:  W J Munckhof; G Borlace; J D Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

5.  Estimating potency for the Emax-model without attaining maximal effects.

Authors:  R C Schoemaker; J M van Gerven; A F Cohen
Journal:  J Pharmacokinet Biopharm       Date:  1998-10

6.  Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.

Authors:  R Gieschke; J L Steimer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jan-Mar       Impact factor: 2.441

7.  Indirect-response modeling of desmopressin at different levels of hydration.

Authors:  T Callréus; J Odeberg; S Lundin; P Höglund
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

Review 8.  Bioavailability and bioequivalence: an FDA regulatory overview.

Authors:  M L Chen; V Shah; R Patnaik; W Adams; A Hussain; D Conner; M Mehta; H Malinowski; J Lazor; S M Huang; D Hare; L Lesko; D Sporn; R Williams
Journal:  Pharm Res       Date:  2001-12       Impact factor: 4.200

9.  Use of sensitivity functions to characterise and compare the forgiveness of drugs.

Authors:  Patrice Nony; Jean-Pierre Boissel
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

10.  Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.

Authors:  J H M Schellens; B Heinrich; M Lehnert; M E Gore; S B Kaye; P Dombernowsky; R Paridaens; A T van Oosterom; J Verweij; W J Loos; H Calvert; N Pavlidis; H Cortes-Funes; J Wanders; M Roelvink; C Sessa; K Selinger; P S Wissel; T Gamucci; A R Hanauske
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.